Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial.

Anup D PatelMaria Mazurkiewicz-BełdzińskaRichard F ChinAntonio Gil-NagelBoudewijn GunningJonathan J HalfordWendy MitchellMichael Scott PerryElizabeth A ThieleArie WeinstockEduardo DunayevichDaniel CheckettsOrrin Devinsky

Published in: Epilepsia (2021)

Long-term add-on CBD treatment had a similar safety profile as in the original RCTs. Sustained reductions in drop and total seizure frequency were observed for up to 156 weeks, demonstrating long-term benefits of CBD treatment for patients with LGS.

Keyphrases

open label
clinical trial
study protocol
phase ii
randomized controlled trial
radiation therapy
phase ii study
smoking cessation